Kaletra Tablets Offer Convenience Benefits, Abbott Says
This article was originally published in The Pink Sheet Daily
Executive SummaryThe firm plans to transition all patients on Kaletra (lopinavir/ritonavir) capsules to the new tablet formulation, which reduces the pill count and eliminates the need for refrigeration.
You may also be interested in...
Allergan has tried to go after alopecia in the past; Exicure brings a new spherical nucleic acid (SNA) technology. In other recent deals, AstraZeneca sells Seroquel, Losec rights to Germany’s Cheplapharm.
CheckMate-9LA testing nivolumab plus ipilimumab plus chemo was stopped early due to a survival win. The promise of another foothold in first-line lung cancer could buoy investors ahead of what could be disappointing Q3 sales.